Johnson & Johnson in Court Again over Antipsychotic Drug, Risperdal
By Joe Messa
In November 2013, Johnson & Johnson paid over $2 billion in criminal and civil penalties and fines for their part in the misrepresentative marketing of Risperdal, an antipsychotic drug sold by their subsidiary, Janssen Pharmaceuticals. Nearly a year and a half later, Johnson & Johnson (J&J) is back in court, fighting claims that they marketed […]
Continue reading